Abstract Fibrotic disease is a significant cause of mortality. CCN2 (connective tissue growth factor [CTGF]), a member of the CCN family of matricellular proteins, plays a significant role in driving the fibrogenic effects of cytokines such as transforming growth factor β (TGFβ). It has been proposed that other members of the CCN family can either promote or antagonize the action of CCN2, depending on the context. A recent elegant study published by Bruce Riser and colleagues (Am J Pathol. 174:1725-34, 2009) illustrates that CCN3 (nov) antagonizes the fibrogenic effects of CCN2. This paper, the subject of this commentary, raises the intriguing possibility that CCN3 may be used as a novel anti-fibrotic therapy.
Fibrotic disease is a significant cause of mortality, and contributes substantially to the global health care costs. Although fibrosis is believed to arise due to the excessive action of fibrogenic cytokines (Krieg et al. 2007) , there is no effective treatment. Owing to its ability to promote TGFβ signaling and fibroblast activation (Grotendorst 1997; Shi-wen et al. 2006; Kennedy et al. 2007 ) and its overexpression in a wide variety of fibrotic diseases, CCN2 is considered to represent a novel target for anti-fibrotic drug intervention (Blom et al. 2002; Leask et al. 2009 ).
CCN2, a cysteine-rich secretory protein of 36 to 38 kDa, has four distinct modules which are shared by most other members of the CCN family of matricellular proteins (Leask and Abraham 2006) . How these proteins influence such a range of functions remains incompletely understood but is likely related this modular nature and a complex array of intra-and inter-molecular interactions with a variety of regulatory proteins and ligands (including cell surface integrins), which are likely to differ among the different CCN proteins (Holbourn et al. 2008) . For example, it has long been recognized that CCN1 (CYR61) and CCN2 promote, whereas CCN3 suppresses, cancer cell growth (Perbal 2001) . These results raise the possibility that CCN3 may act to prevent the pathological actions of CCN1 or CCN2.
In a recent report, Riser and colleagues (2009) show that, in cultured kidney mesangial cells, CCN3 is normally expressed. TGF-β reduces CCN3 expression but increases CCN2 and collagen type I expression. Addition of CCN3 or CCN3 overexpression caused down-regulation of CCN2 and collagen type I. The action of CCN3 did not depend on cell proliferation or on Smad signaling. CCN3 acted on the type I collagen minimal promoter.
The mechanism underlying CCN3 action was not identified, but could arise due to the engagement of different integrins resulting in the activation of different non-Smad signaling pathways (e.g., p38, JNK, ERK) , which are known to affect fibrotic responses (Leask and Abraham 2004) . Alternatively, different extracellular ligands may be recruited to the cell surface in the presence of CCN2 alone versus the presence of CCN2 together with CCN3 (Perbal 2004) . Identification of the precise elements in the type I collagen promoter which respond to CCN3 would be extremely informative. Nonetheless, these data support the idea that the different combinations of CCN proteins present in one locale can result in divergent biological effects and, moreover, that CCN3 may represent a novel, biological antifibrotic treatment.
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